Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation
Recruiting · NCT07623473 · Observational (researchers observe without assigning treatment) · Lead sponsor: Herlev and Gentofte Hospital
View the official record on ClinicalTrials.gov →Interventions studied
Blood tests
What this trial is about
The goal of the NIMBLE study is to evaluate blood-based biomarkers for lung cancer risk prediction in patients referred with a lung nodule. Each blood biomarker will be evaluated for descriminating malignant from benign lung nodules alone and in combination with other blood biomarkers, patient characteristics and radiological features.
Who can take part
Age range
No age limits stated
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patients with a newly detected IPN suspected of lung cancer referred to the infiltrate unit
- Having signed informed consent
Exclusion criteria
- Active cancer, excluding non-melanoma skin cancer
- Comorbidities that exclude the patient from clinical follow-up and final diagnosis
Where it is running
1 location listed.
- Gentofte Hospital - Gentofte Municipality, Denmark